KCG
ATHE

Knight Capital Group’s Alterity Therapeutics ATHE Stock Holding History

Knight Capital Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$27K Buy
+195
New +$26.5K ﹤0.01% 3147

Other funds holding ATHE

GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Knight Capital Group's ATHE Position: Q2 2013 in Review

Knight Capital Group opened a new position in Alterity Therapeutics (ATHE) in Q2 2013: 195 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #3147 among its holdings.

10 funds tracked by Wall St. Rank hold ATHE as of Q2 2013.

  • Knight Capital Group held 195 shares of Alterity Therapeutics worth $27K as of Q2 2013.
  • Alterity Therapeutics was a new Knight Capital Group position in Q2 2013.
  • Alterity Therapeutics made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3147 holding.
  • 10 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.